Attitude Towards and Perception of Individual Safety After SARS-CoV-2 Vaccination Among German Cancer Patients

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2022 Jun 22

PMID 35731276

Authors

Oliver Overheu

Simon Lendowski

Daniel R Quast

Corinna S Marheinecke

Eleni Kourti

Celine Lugnier

Ioana Andreica

Uta Kiltz

Stephanie Pfaender

Anke Reinacher-Schick

Affiliations

Soon will be listed here.

Abstract

Purpose: Refusal to receive SARS-CoV-2 vaccination poses a threat to fighting the COVID-19 pandemic. Little is known about German cancer patients' attitude towards and experience with SARS-CoV-2 vaccination.

Methods: Patients were enrolled between 04-11/2021. They completed a baseline questionnaire (BLQ) containing multiple choice questions and Likert items ranging from 1 ("totally disagree") to 11 ("totally agree") regarding their attitude towards vaccination and COVID-19. A follow-up questionnaire (FUQ) was completed after vaccination.

Results: 218 patients (43% female) completed BLQ (110 FUQ; 48% female). Most patients agreed to "definitely get vaccinated" (82%) and disagreed with "SARS-CoV-2 vaccination is dispensable due to COVID-19 being no serious threat" (82%; more dissent among men, p = 0.05). Self-assessment as a member of a risk group (p = 0.03) and fear of COVID-19 (p = 0.002) were more common among women. Fear of side effects was more common among women (p = 0.002) and patients with solid or GI tumors (p = 0.03; p < 0.0001). At FUQ, almost all (91%) reported their vaccination to be well tolerated, especially men (p = 0.001). High tolerability correlated with confidence in the vaccine being safe (r = 0.305, p = 0.003). Most patients would agree to get it yearly (78%). After vaccination, patients felt safe meeting friends/family (91%) or shopping (62%). Vacation (32%) or work (22%) were among others considered less safe (less frequent among men, p < 0.05).

Conclusion: Acceptance of SARS-CoV-2 vaccination is high and it is well tolerated in this sensitive cohort. However, concerns about vaccine safety remain. Those and gender differences need to be addressed. Our results help identify patients that benefit from pre-vaccination consultation.

Citing Articles

Association of self-leadership and epidemic risk perception on quality of life in post-pandemic mainland of China: a cross-sectional study.

Ren J, Zhu Y, He Y, Zhao X, Pang G, Long L Front Public Health. 2024; 12:1394416.

PMID: 38983255 PMC: 11231097. DOI: 10.3389/fpubh.2024.1394416.

Immune response of COVID-19 vaccines in solid cancer patients: A meta-analysis.

Hua T, Fan R, Fan Y, Chen F Hum Vaccin Immunother. 2024; 20(1):2357424.

PMID: 38785118 PMC: 11135846. DOI: 10.1080/21645515.2024.2357424.

Prevalence and factors of COVID-19 vaccine refusal among solid cancer patients in China: an application of the health belief model.

Xie Z, Lau J, Liang Y, Ouyang Q, Chen J, Lin S Front Public Health. 2023; 11:1236376.

PMID: 37601174 PMC: 10435902. DOI: 10.3389/fpubh.2023.1236376.

Longitudinal data on humoral response and neutralizing antibodies against SARS-CoV-2 Omicron BA.1 and subvariants BA.4/5 and BQ.1.1 after COVID-19 vaccination in cancer patients.

Overheu O, Lendowski S, Quast D, Kuhn D, Vidal Blanco E, Kraeft A J Cancer Res Clin Oncol. 2023; 149(12):10633-10644.

PMID: 37300723 PMC: 10257184. DOI: 10.1007/s00432-023-04961-2.

Adherence to Sars-CoV2 vaccination in hematological patients.

Narinx J, Houbiers M, Seidel L, Beguin Y Front Immunol. 2022; 13:994311.

PMID: 36300128 PMC: 9588907. DOI: 10.3389/fimmu.2022.994311.

References

Addeo A, Shah P, Bordry N, Hudson R, Albracht B, Di Marco M . Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer. Cancer Cell. 2021; 39(8):1091-1098.e2. PMC: 8218532. DOI: 10.1016/j.ccell.2021.06.009. View

Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020; 397(10269):99-111. PMC: 7723445. DOI: 10.1016/S0140-6736(20)32661-1. View

Ogilvie G, Gordon S, Smith L, Albert A, Racey C, Booth A . Intention to receive a COVID-19 vaccine: results from a population-based survey in Canada. BMC Public Health. 2021; 21(1):1017. PMC: 8164402. DOI: 10.1186/s12889-021-11098-9. View

Chun J, Kim S, Park E, Park S, Koh S, Cha Y . Cancer Patients' Willingness to Take COVID-19 Vaccination: A Nationwide Multicenter Survey in Korea. Cancers (Basel). 2021; 13(15). PMC: 8345425. DOI: 10.3390/cancers13153883. View

Heyerdahl L, Vray M, Lana B, Tvardik N, Gobat N, Wanat M . Conditionality of COVID-19 vaccine acceptance in European countries. Vaccine. 2022; 40(9):1191-1197. PMC: 8806150. DOI: 10.1016/j.vaccine.2022.01.054. View

Holzmann-Littig C, Braunisch M, Kranke P, Popp M, Seeber C, Fichtner F . COVID-19 Vaccination Acceptance and Hesitancy among Healthcare Workers in Germany. Vaccines (Basel). 2021; 9(7). PMC: 8310090. DOI: 10.3390/vaccines9070777. View

Barriere J, Gal J, Hoch B, Cassuto O, Leysalle A, Chamorey E . Acceptance of SARS-CoV-2 vaccination among French patients with cancer: a cross-sectional survey. Ann Oncol. 2021; 32(5):673-674. PMC: 7846886. DOI: 10.1016/j.annonc.2021.01.066. View

Shakeel C, Mujeeb A, Mirza M, Chaudhry B, Khan S . Global COVID-19 Vaccine Acceptance: A Systematic Review of Associated Social and Behavioral Factors. Vaccines (Basel). 2022; 10(1). PMC: 8779795. DOI: 10.3390/vaccines10010110. View

Neumann-Bohme S, Varghese N, Sabat I, Pita Barros P, Brouwer W, van Exel J . Once we have it, will we use it? A European survey on willingness to be vaccinated against COVID-19. Eur J Health Econ. 2020; 21(7):977-982. PMC: 7317261. DOI: 10.1007/s10198-020-01208-6. View

10.

Umakanthan S, Lawrence S . Predictors of COVID-19 vaccine hesitancy in Germany: a cross-sectional, population-based study. Postgrad Med J. 2023; 98(1164):756-764. DOI: 10.1136/postgradmedj-2021-141365. View

11.

Fendler A, de Vries E, GeurtsvanKessel C, Haanen J, Wormann B, Turajlic S . COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety. Nat Rev Clin Oncol. 2022; 19(6):385-401. PMC: 8916486. DOI: 10.1038/s41571-022-00610-8. View

12.

Overheu O, Quast D, Schmidt W, Sakinc-Guler T, Reinacher-Schick A . Low Serological Prevalence of SARS-CoV-2 Antibodies in Cancer Patients at a German University Oncology Center. Oncol Res Treat. 2021; 45(3):112-117. PMC: 8805057. DOI: 10.1159/000520572. View

13.

Polack F, Thomas S, Kitchin N, Absalon J, Gurtman A, Lockhart S . Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020; 383(27):2603-2615. PMC: 7745181. DOI: 10.1056/NEJMoa2034577. View

14.

de Sousa M, Caramujo C, Julio N, Magalhaes J, Basto R, Fraga T . Acceptance of SARS-CoV-2 vaccination among cancer patients in Portugal: attitudes and associated factors. Support Care Cancer. 2022; 30(5):4565-4570. PMC: 8815020. DOI: 10.1007/s00520-022-06886-x. View

15.

Heyne S, Esser P, Werner A, Lehmann-Laue A, Mehnert-Theuerkauf A . Attitudes toward a COVID-19 vaccine and vaccination status in cancer patients: a cross-sectional survey. J Cancer Res Clin Oncol. 2022; 148(6):1363-1374. PMC: 8881553. DOI: 10.1007/s00432-022-03961-y. View

16.

Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z . Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak. Cancer Discov. 2020; 10(6):783-791. PMC: 7309152. DOI: 10.1158/2159-8290.CD-20-0422. View

17.

Pertwee E, Simas C, Larson H . An epidemic of uncertainty: rumors, conspiracy theories and vaccine hesitancy. Nat Med. 2022; 28(3):456-459. DOI: 10.1038/s41591-022-01728-z. View

18.

Thunstrom L, Ashworth M, Finnoff D, Newbold S . Hesitancy Toward a COVID-19 Vaccine. Ecohealth. 2021; 18(1):44-60. PMC: 8175934. DOI: 10.1007/s10393-021-01524-0. View

19.

Latkin C, Dayton L, Yi G, Colon B, Kong X . Mask usage, social distancing, racial, and gender correlates of COVID-19 vaccine intentions among adults in the US. PLoS One. 2021; 16(2):e0246970. PMC: 7886161. DOI: 10.1371/journal.pone.0246970. View

20.

Bar-On Y, Goldberg Y, Mandel M, Bodenheimer O, Amir O, Freedman L . Protection by a Fourth Dose of BNT162b2 against Omicron in Israel. N Engl J Med. 2022; 386(18):1712-1720. PMC: 9006780. DOI: 10.1056/NEJMoa2201570. View